Tamoxifen Retinopathy and Macular Telangiectasia Type 2 Similarities and Differences on Multimodal Retinal Imaging

被引:4
|
作者
Hess, Kristina [1 ,2 ]
Park, Yu Jeong [3 ]
Kim, Hyun-Ah [3 ]
Holz, Frank G. [1 ]
Issa, Peter Charbel [4 ,5 ]
Yoon, Young Hee [3 ]
Tzaridis, Simone [1 ,6 ,7 ]
机构
[1] Univ Bonn, Dept Ophthalmol, Bonn, Germany
[2] NEI, NIH, Bethesda, MD USA
[3] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Ophthalmol, Seoul, South Korea
[4] Oxford Univ Hosp NHS Fdn Trust, Oxford Eye Hosp, Oxford, England
[5] Univ Oxford, Dept Clin Neurosci, Nuffield Lab Ophthalmol, Oxford, England
[6] Lowy Med Res Inst, 3366 N Torrey Pines Court,Suite 300, La Jolla, CA 92037 USA
[7] Scripps Res Inst, Dept Mol Med, La Jolla, CA USA
来源
OPHTHALMOLOGY RETINA | 2023年 / 7卷 / 02期
关键词
OPTICAL COHERENCE TOMOGRAPHY; DISEASE; MACTEL;
D O I
10.1016/j.oret.2022.08.004
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: Tamoxifen-induced retinopathy (TR) and macular telangiectasia type 2 (MacTel) share a highly similar retinal phenotype. In this study, we aimed to evaluate differences and similarities that may point toward underlying mechanisms linking both disease entities.Design: Retrospective, cross sectional study.Subjects: Patients diagnosed with MacTel or TR.Methods: Patients underwent multimodal retinal imaging, including color fundus photography, spectral -domain OCT, fundus autofluorescence, fluorescein angiography, and OCT angiography (if available). Age, age of onset, best-corrected visual acuity, and bilaterality of changes were evaluated. Patients' eyes were graded for different morphologic characteristics by 4 experienced graders.Main Outcome Measures: Phenotypical characterization and comparison of frequencies of retinal char-acteristics of TR and MacTel on multimodal imaging.Results: Twenty-eight eyes of 14 patients with TR and 118 eyes of 59 patients with MacTel were included. Age, age of onset, and best-corrected visual acuity were similar in both cohorts. All but 1 patient showed bilateral changes. In patients with MacTel, neurodegenerative changes and vascular alterations were equally present, whereas in patients with TR, neurodegenerative changes usually prevailed. Predilection sites within the central retina differed between the 2 diseases: most findings in patients with TR were limited to the foveal center, whereas changes in patients with MacTel were present throughout a slightly larger region ("MacTel area"), with an epicenter temporal to the foveal center. Distinct morphologic features included the distribution of retinal crystals, the size and position of ellipsoid zone breaks, and the presence of hyperreflective changes on OCT images. Focal hyperpigmentation and neovascular membranes were only present in eyes with MacTel.Conclusions: Macular telangiectasia and TR share a highly similar retinal phenotype, especially in early disease stages. Subtle differences on multimodal retinal images may help distinguish between these 2 disease entities. Our findings indicate the involvement of Muller cells in both diseases, which may explain the observed phenotypic characteristics and similarities. Ophthalmology Retina 2023;7:101-110 & COPY; 2022 by the American Academy of Ophthalmology
引用
收藏
页码:101 / 110
页数:10
相关论文
共 50 条
  • [31] CHOROIDAL THICKNESS IN MACULAR TELANGIECTASIA TYPE 2
    Chhablani, Jay
    Kozak, Igor
    Jonnadula, Ganesh Babu
    Venkata, Amarnath
    Narayanan, Raja
    Pappuru, Rajeev Reddy
    Rao, Podili Srinivas
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2014, 34 (09): : 1819 - 1823
  • [32] DARK ADAPTATION IN MACULAR TELANGIECTASIA TYPE 2
    Tzaridis, Simone
    Hess, Kristina
    Heeren, Tjebo F. C.
    Nadal, Jennifer
    Mai, Clarissa
    Herrmann, Philipp
    Issa, Peter Charbel
    Holz, Frank G.
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2020, 40 (10): : 2018 - 2025
  • [33] Morphological characteristics in macular telangiectasia type 2
    Charbel, P.
    Heeren, T. F. C.
    Krueger, E.
    Zeimer, M.
    Pauleikhoff, D.
    Holz, F. G.
    OPHTHALMOLOGE, 2014, 111 (09): : 819 - 828
  • [34] SEX STEROIDS AND MACULAR TELANGIECTASIA TYPE 2
    Mueller, Simone
    Allam, Jean-Pierre
    Bunzek, Christopher G.
    Clemons, Traci E.
    Holz, Frank G.
    Charbel, Peter
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2018, 38 : S61 - S66
  • [35] Genetic Background of Macular Telangiectasia Type 2
    Kuncic, Ajda
    Urbancic, Mojca
    Divjak, Darja Dobovsek
    Hudler, Petra
    Debeljak, Natasa
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2025, 26 (02)
  • [36] Familial Asymptomatic Macular Telangiectasia Type 2
    Gillies, Mark C.
    Zhu, Meidong
    Chew, Emily
    Barthelmes, Daniel
    Hughes, Edward
    Ali, Haipha
    Holz, Frank G.
    Scholl, Hendrik P. N.
    Issa, Peter Charbel
    OPHTHALMOLOGY, 2009, 116 (12) : 2422 - 2429
  • [37] Multimodal imaging in diabetic retinopathy and macular edema: An update about biomarkers
    Parravano, Mariacristina
    Cennamo, Gilda
    Di Antonio, Luca
    Grassi, Maria Oliva
    Lupidi, Marco
    Rispoli, Marco
    Savastano, Maria Cristina
    Veritti, Daniele
    Vujosevic, Stela
    SURVEY OF OPHTHALMOLOGY, 2024, 69 (06) : 893 - 904
  • [38] FLUORESCENCE LIFETIME IMAGING OPHTHALMOSCOPY IN PATIENTS WITH MACULAR TELANGIECTASIA TYPE 2 WITH AND WITHOUT DIABETES
    Sauer, Lydia
    Vitale, Alexandra S.
    Jacoby, Rachael S.
    Hart, Barbara
    Bernstein, Paul S.
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2023, 43 (09): : 1597 - 1607
  • [39] Intravitreal Bevacizumab for Type 2 Idiopathic Macular Telangiectasia
    Veloso, Carlos E.
    Vianna, Raul N.
    Pelayes, David E.
    Nehemy, Marcio B.
    OPHTHALMIC RESEARCH, 2013, 49 (04) : 205 - 208
  • [40] Progression of Vision Loss in Macular Telangiectasia Type 2
    Heeren, Tjebo F. C.
    Clemons, Traci
    Scholl, Hendrik P. N.
    Bird, Alan C.
    Holz, Frank G.
    Issa, Peter Charbel
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (06) : 3905 - 3912